ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis

PURPOSE: In women with postmenopausal osteoporosis, we investigated the effects of 24 months of treatment with alendronate (ALN) following 18 months of treatment with abaloparatide (ABL) or placebo (PBO). METHODS: Women who completed ABL or PBO treatment in ACTIVE were eligible to receive up to 24 m...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Endocrinol Metab
Главные авторы: Bone, Henry G, Cosman, Felicia, Miller, Paul D, Williams, Gregory C, Hattersley, Gary, Hu, Ming-yi, Fitzpatrick, Lorraine A, Mitlak, Bruce, Papapoulos, Socrates, Rizzoli, René, Dore, Robin K, Bilezikian, John P, Saag, Kenneth G
Формат: Artigo
Язык:Inglês
Опубликовано: Endocrine Society 2018
Предметы:
Clinical Research Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6097601/
https://ncbi.nlm.nih.gov/pubmed/29800372
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2018-00163
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы